Summary & Overview
HCPCS J3031: Injection, fremanezumab‑vfrm, 1 mg
HCPCS Level II code J3031 represents injection dosing of fremanezumab‑vfrm billed per 1 mg when the medication is administered under the direct supervision of a physician. This code captures provider‑administered doses of a monoclonal antibody used in migraine prevention and is relevant for payers managing specialty drug utilization and outpatient infusion services nationally. The code matters because specialty biologics drive significant pharmacy and medical spend, and correct use of the HCPCS billing pathway affects coverage, billing compliance, and site‑of‑service reporting.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical and billing context for J3031, common payer interactions, and the typical service settings where the code applies. The publication outlines benchmarks and reimbursement considerations where available, highlights policy and coverage implications for administered biologic therapies, and situates J3031 within outpatient administration workflows. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3031 describes the drug product fremanezumab‑vfrm, billed per 1 mg for injections. The code is intended for use when the drug is administered under the direct supervision of a physician and is not for self‑administered formulations.
Service Type: Injectable biologic medication administration
Typical Site of Service: Outpatient clinic, physician office, or infusion/administration setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old female with a documented history of chronic migraine refractory to at least two classes of preventive medications presents to a neurology infusion suite for administration of fremanezumab-vfrm. The medication is billed using J3031 and is administered by a registered nurse under the direct supervision of a neurologist. The typical workflow includes verification of identity and consent, review of migraine frequency and prior preventive therapies, medication preparation and labeling by pharmacy, documentation of lot number and dose, subcutaneous injection (per product instructions), 30-minute observation for immediate adverse reactions, and discharge with aftercare instructions and a follow-up appointment. The typical site of service is an office-based infusion/observation area or an outpatient clinic where the drug cannot be self-administered and must be given under physician supervision for Medicare billing. Clinical documentation includes indication (e.g., chronic migraine), prior preventive treatment history, informed consent for administration, injection site assessment, medication administration record with J3031 units correlated to milligrams given, and any immediate adverse events or patient education provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier information |